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ABSTRACT 
This thesis deals with the importance of hepatic iron and fat deposition in the context of chronic 
liver disease, with special focus on the role of the S65C mutation in the hemochromatosis 
(HFE) gene, the association between non-alcoholic fatty liver disease (NAFLD) and 
cryptogenic cirrhosis (CC) in patients evaluated for liver transplantation, the expressions of  
innate and adaptive immunity in non-alcoholic steatohepatitis (NASH), and the role of the iron 
regulatory hormone hepcidin in dysmetabolic iron overload (DIO). 
  
NAFLD is the most common liver disease in the Western world. Some patients with NAFLD 
develop NASH and are then at risk for progressive liver disease, cirrhosis and hepatocellular 
carcinoma. NASH involves the innate immune system, but the role of the adaptive immune 
system in this context is less clear. A subgroup of patients with NAFLD develops DIO, the 
causes of which are unknown. Mutations of the HFE gene may be associated with DIO, but 
results are conflicting. The role of the most recently found HFE mutation, S65C, has not been 
known. Finally, in end-stage NASH cirrhosis, liver fat diminishes, and patients with CC may 
therefore have an underlying NAFLD. 
 
In study I the HFE S65C gene mutation was retrospectively studied in 296 patients with 
suspected iron overload and 250 healthy controls in order to determine the HFE S65C 
frequency, and evaluate whether this mutation would result in a significant hepatic iron 
overload or not. We found that the S65C allele was enriched in patients with high serum ferritin 
compared with controls, and half of the carriers of this allele had mild or moderate hepatic iron 
overload, but no signs of significant fibrosis. 
 
In study II, 39 patients with CC were compared with 431 patients having cirrhosis of other 
etiologies, to evaluate the presence of NAFLD in patients with CC and determine survival after 
liver transplantation. We found that 44% of the CC patients had an underlying NAFLD. CC 
patients had a higher frequency of diabetes, ascites, and hyponatremia compared with those 
having cirrhosis of other etiologies. Weight loss was significantly higher among patients with 
CC, but there was no difference in patient survival between the groups. 
 
In study III, liver biopsies from 49 patients with suspected NAFLD were classified according to 
the NAFLD Activity Score (NAS) and liver fat was assessed with morphometry. Biopsies were 
stained with various markers of T-cells, macrophages, apoptosis and cell adhesion molecules 
(ICAM-1). We found an increased number of regulatory T-cells (Tregs) and CD68 cells in 
NASH, pointing at an involvement of both the adaptive and innate immune systems. ICAM-1-
positive hepatocytes were only seen in NASH livers and localized in areas with microvesicular 
fat, and the ICAM-1 level in serum was increased in patients with NASH. 
Study IV aimed to determine the association between hepcidin and iron parameters, lipid status 
and inflammatory markers in NAFLD in relation to other chronic liver diseases. Serum hepcidin 
was analyzed in 85 patients with chronic liver disease (38 of which had NAFLD) and 38 
healthy controls. Liver biopsy was performed in 67 patients and hepcidin mRNA in liver was 
determined with real time-qPCR in 36 patients.  We found that hepcidin regulation was similar 
in NAFLD compared to other chronic liver diseases with various degrees of hepatic iron 
overload. In NAFLD hepcidin correlated to serum ferritin and liver iron, but not to BMI, CRP, 
NAS or steatosis. Transferrin saturation, but not hepcidin, could be used to discriminate 
between hyperferritinemic NAFLD patients with or without iron overload. 
 
In conclusion, we found that the HFE S65C mutation leads to mild to moderate hepatic iron 
overload, but neither to clinically manifest hemochromatosis, nor extensive liver fibrosis. Re-
evaluation of patient data in cryptogenic cirrhosis discovered underlying NAFLD in 44% of 
patients evaluated for liver transplantation. There was no difference in patient survival between 
cryptogenic patients and those having cirrhosis of a known etiology. In NASH, an involvement 
of the innate adaptive immunity is seen, and immunohistochemical markers of inflammation are 
localized to areas of microvesicular steatosis. Serum hepcidin levels in patients with NAFLD 
correlate adequately to iron parameters, but not to BMI, NAS or inflammatory markers. 
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1 INTRODUCTION  
In this thesis, we have aimed to characterize clinical features and underlying pathogenic 
mechanisms of iron and fat infiltration in the livers of patients with suspected iron overload 
and/or non-alcoholic fatty liver disease. Our patient cohorts include those with elevated serum 
ferritin, chronic liver disease, non-alcoholic fatty liver disease (NAFLD) with or without non-
alcoholic steatohepatitis (NASH), and/or cryptogenic end-stage cirrhosis. In the Western world, 
NAFLD has become the most common liver disease, possibly because the prevalence of obesity 
and type 2 diabetes is rising worldwide. Fatty liver was considered a benign condition, but 
today we know that patients with NASH are at risk of progressive liver disease, and NASH-
cirrhosis has become a common indication for liver transplantation. The problem of fatty liver is 
not limited to patients with NAFLD. Steatosis as a co-factor in chronic liver disease has been 
recognized in chronic hepatitis C, alcoholic liver disease, and hemochromatosis.1, 2 Hereditary 
hemochromatosis is an iron overload disorder caused by mutations resulting in insufficient 
hepcidin secretion which in turn leads to increased uptake of dietary iron. Excess iron is stored 
in parenchymal organs. The liver is particularly vulnerable to the toxic effects of iron since it is 
the main site of iron storage. If the excess iron is not removed there is a risk of oxidative stress 
and fibrogenesis.3 Iron overload has also proven to be a co-factor in other liver disease, not the 
least due to the link between iron stores and insulin resistance.4  In NAFLD, iron has been 
proposed as a pathogenic factor for NASH development, and iron reduction therapy suggested 
as a treatment option. Thus, steatosis and iron overload is not only important in NAFLD and 
hemochromatosis, but also in chronic liver disease in general.   
1.1 IRON HOMEOSTASIS  
Iron homeostasis requires coordination between tissues that export iron into plasma (duodenal 
mucosa, macrophages) tissues that utilize iron (mainly red blood cell precursors), and tissues 
that store iron (such as hepatocytes, pancreatic cells and cardiac cells). The iron storage protein, 
ferritin, reflects iron stores in normal conditions, but not in the case of inflammation or liver 
damage. The amount of iron in an average adult is 3–4 g. To support erythropoiesis and other 
metabolic processes about 25 mg iron/ day is needed. Aged erythrocytes stand for the 
predominant contribution, and only 1-2 mg of dietary iron is absorbed from enterocytes in 
normal conditions, equaling the amount of daily loss. Iron is distributed through blood plasma, 
where it is bound to the iron transport protein transferrin. The body is dependent on regulation 
of the dietary uptake of iron, since losses are not modulated by iron excess or deficiency. The 
small peptide hepcidin is the master regulatory hormone of systemic iron metabolism. It is 
expressed in the liver and inhibits iron recycling from macrophages and enterocytes, by binding 
to and inducing the degradation of the cellular iron exporter ferroportin, thus lowering iron 
levels in serum. Consequently, deficiency of hepcidin will lead to iron overload.5-7 Mutations in 
four different genes have been identified to result in hereditary hemochromatosis. These are the 
structural gene for hepcidin HAMP, and genes that are required for the expression of hepcidin 
through interaction with iron, hemojuvelin (HJV), tranferrin receptor 2 (TfR 2), and HFE. Iron 
regulation is also dependent on the Bone morphogenic protein (BMP) pathway, mostly BMP 6. 
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BMP 6 increases when liver iron concentration is high indicating that BMP6 could work as an 
indicator of iron storage.  The BMP6 co-receptor HJV enhances the BMP receptors affinity for 
its ligands and boosts hepcidin transcription. Mutations in HJV decrease hepcidin to levels as 
low as those seen in patients with mutations in HAMP. Mutations in these genes lead to juvenile 
hemochromatosis, the most severe form of genetic iron overload disease. Inflammation 
increases levels of hepcidin since its synthesis is induced by IL-6. Decrease of hepcidin 
synthesis is thought to be the cause of iron overload in chronic liver disease and alcohol 
overconsumption.8 In obesity, the low grade inflammation and expression of hepcidin in 
adipose tissue, might explain why iron deficiency is common in this condition.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. In normal iron homeostasis transferrin bound iron will stimulate hepcidin synthesis by 
interaction with HFE, TfR2 and HJV.  BMP is of crucial importance to hepcidin regulation and HJV 
acts as a co-receptor for BMP-6. Hepcidin causes ferroportin to be internalized and thus blocks the 
pathway for iron transfer from enterocytes and macrophages into plasma. Hepcidin synthesis is induced 
by IL-6. Blood loss, anemia and hypoxia, leads to decrease in hepcidin production through erythropoetic 
stimuli. 
ferroportin ferroportin 
Enterocyte Macrophage 
Hepcidin 
Iron Iron 
Hepatocyte 
HFE 
TfR2 
HJV 
BMP 
IL-6 
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1.2 IRON TOXICITY   
In switching between its ferric (FeIII) and ferrous (FeII) form, iron has the ability to easily 
donate and accept electrons. This makes iron essential for various processes, most importantly 
those of oxygen transport. However, iron can also be harmful. To prevent its harmful effects, 
iron is bound to transferrin in the circulation and stored by ferritin. In normal conditions there 
are hardly any notable levels of free or labile iron. In the case of iron overload disorders, free 
iron catalyzes the production of highly toxic hydroxyl radicals through the Fenton and Haber-
Weiss reactions. 
 
 
 
 
 
 
Figure 2. Iron catalyzes the production of hydroxyl radicals (OH.) from superoxide (O2-˙) and hydrogen 
peroxidase (H2O2). 
This, in turn may lead to peroxidation of organelle membrane lipids. Antioxidant defense 
mechanisms counterbalance this process, but as iron overload increases, they become 
insufficient.10-12 In hemochromatosis massive iron overload may cause cell death and the 
initiation of fibrogenesis. If the excess iron is not removed there can be a progress to cirrhosis.13 
1.3 HEREDITARY HEMOCHROMATOSIS  
Hereditary hemochromatosis (HH) is the most common autosomal recessive disorder in 
Caucasians, affecting 1 in every 200-400 persons.14 It may lead to enhanced iron absorption and 
progressive iron disposal in parenchymal organs, most notably in the liver. With time, excess 
iron may cause damage to parenchymal organs with an increased risk of developing diabetes 
mellitus, arthropathy, liver cirrhosis, and hepatocellular carcinoma.15 HH is divided in four 
types. Type 1 is the HFE-related HH, also referred to as classic hereditary hemochromatosis. 
Type 2, also called juvenile hemochromatosis, is caused by mutations in the HJV gene (subtype 
A), and in the HAMP gene (subtype B). Type 3 is caused by mutations in the TfR2 gene. Type 
4 is an autosomal dominant condition with heterozygous mutations in the ferroportin 1 gene.14 
These different types of HH differ greatly in phenotypic expression, but types 1-3 share 
inappropriate hepcidin levels as a common pathogenetic factor.16  
Type 1 is the most common, responsible for more than 80% of cases in patients of European 
descent.17 Homozygocity for the substitution of cysteine for tyrosine at amino acid position 282 
Fe2+ + H2O2 → Fe3+ + OH˙ + OH¯ (Fenton) 
Fe3+ + O2-˙→ Fe2+ + O2 
Net reaction:  
                        Fe 
H2O2 + O2-˙		→			OH˙ + OH¯ + O2 (Haber-Weiss) 
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(C282Y) in the HFE protein is the dominating mutation. In the H63D mutation aspartate 
replaces histidine at amino acid position 63 in the HFE protein.18 The H63D mutation does not 
by itself cause hemochromatosis, not even in its homozygous form. In combination with the 
C282Y mutation, i.e. compound heterozygocity, there is a risk of iron overload. However it 
tends to be milder compared to that of C282Y homozygocity, and comorbid factors such as 
alcohol overconsumption or steatosis are probably needed for clinical disease progression.19 
C282Y heterozygocity alone is not considered to be responsible for iron overload, but there are 
data supportive of a protective role against iron deficiency.20, 21 A third HFE-mutation, S65C, 
has been associated with mild to moderate hepatic iron overload. However, there are no studies 
that have associated the S65C mutation to extensive liver fibrosis.22-25  
Treatment of hemochromatosis consists of weekly phlebotomies, removing 400-500 ml each 
time until S-ferritin is about 50 µg/l. When iron stores are depleted patients continue treatment 
with phlebotomies 2-6 times a year. The prognosis in HH is good with adequate treatment.  In 
pre-cirrhotic, non-diabetic patients, life expectancy is normal.26 Early detection is desirable, but 
screening of the general population is often argued against because of low disease penetrance. 
Screening of first degree relatives, especially in siblings, is usually recommended.17, 27  
1.4 NAFLD AND NASH 
Nonalcoholic fatty liver disease (NAFLD) is a common condition that defines a spectrum of 
alcohol-like liver disease in the absence of significant alcohol use, genetic, viral and 
autoimmune etiologies.28 Within this spectrum patients with NASH (Nonalcoholic 
steatohepatitis) are at risk of developing progressive liver disease, cirrhosis and hepatocellular 
carcinoma.29 It has also been suggested that NASH could be a leading cause of cryptogenic 
cirrhosis.30, 31 Among factors that are predominantly described to be associated with NASH are 
insulin resistance or non-insulin dependent diabetes, obesity, and dyslipidemia.32 Today 
NAFLD is generally regarded as the liver manifestation of the metabolic syndrome.33 The term 
NASH was first used in 1980 to describe histopathological findings indistinguishable from 
those of alcoholic liver disease in obese subjects without significant alcohol use.34 Coining of 
this term likely helped to put more focus on the condition in the coming years. 
The common definition of NAFLD is presence of at least 5% steatosis in the liver. The 
histological diagnosis of NASH is dependent on multiple lesions within the liver parenchyma 
which has prompted the development of scoring systems. Kleiner has presented a validated 
histological feature scoring system addressing the lesions of NAFLD and proposed a NAFLD 
activity score (NAS) for use in clinical trials. This score is defined as the unweighted sum of the 
scores for steatosis (0-3), lobular inflammation (0-3), and ballooning (0-2); thus ranging from 0-
8. Fibrosis is separated from other features of activity. A NAS of 5 or more correlates with 
NASH, scores of 2 or less are not diagnostic of steatohepatitis. The term “borderline NASH” is 
used for scores of 3-4.35 Hence, NAFLD is a clinicopathologic diagnosis, and one cannot 
overlook the sometimes thin line between NAFLD and alcoholic fatty liver disease. Most 
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studies allow for a daily intake of alcohol of less than 30 grams for men and 20 grams for 
women.36 In everyday clinical practice the distinction between NASH and ASH is not always 
clear. Studies have shown association between moderate alcohol use and the progression of 
hepatic fibrosis in NAFLD. Contrary to these results, several studies have attributed light to 
moderate alcohol use a protective role in NAFLD.37-39  
The prevalence of NAFLD has been estimated to 20-30% in the western world, and that of 
NASH to 2-3%.  As obesity and diabetes in the population increases fatty liver also becomes 
more frequent, constituting a major health problem. However, since fatty liver is very common 
(in some studies up to 50% of the population) there are those who propose that the term NAFL 
(non-alcoholic fatty liver) should be used instead of NAFLD in many cases to avoid that such a 
widespread condition with a predominantly benign course will be regarded as a disease state.40  
The pathogenesis of NASH was initially described as a two-hit process starting with the 
accumulation of fat in the liver. The second hit involves oxidative stress which can promote 
lipid peroxidation in the hepatocytes membrane causing secretion of proinflammatory cytokines 
(such as TNF-α and IL-6), and stellate cell activation, which results in fibrosis.41 Insulin 
resistance is probably the most important factor in the development of NASH. In recent years 
new insights have expanded the original theory on the pathogenesis of NASH in to a multiple-
hit process in which parallel events are thought to interact. This theory comprises dietary 
factors, gut microbiota as well as host genetics. It adds detail as well as complexity to the 
mechanisms underlying the progress from steatosis to steatohepatitis.42   
1.5 INFLAMMATION AND IMMUNITY 
When the body is exposed to harmful stimuli, such as pathogens, damaged cells, or irritants, it 
will respond with inflammation. Inflammation can be classified as either acute which occurs 
over seconds to days, or chronic, which occurs over longer times. Acute inflammation is the 
body´s initial response to harmful stimuli and is achieved by increased movement of leukocytes 
such as plasma cells and granulocytes from the blood into the injured tissues. This recruitment 
of inflammatory cells is mediated through production of chemical factors including cytokines. 
Prolonged, or chronic, inflammation causes a shift in the type of cells present at the site of 
inflammation, mainly to macrophages and lymphocytes i.e. mononuclear cells, and leads to 
simultaneous destruction and healing of the tissue. With intense or chronic inflammation comes 
the risk of scarring and organ dysfunction. Inflammation is one type of the body´s response to 
pathogens. It is non-specific and therefore often described as the dominating mechanism of 
innate immunity, as compared to adaptive immunity, which is a specific response. Innate 
immunity is the first line of host defense. It is rapid and has a broad impact. It includes 
epithelial barriers, complement protein and release of cytokines which in turn regulate the 
function of other cells. Innate immune responses also have the ability of recognizing molecular 
patterns that are shared by many microbes, for example the recognition of lipopolysaccarides by 
toll-like receptors. Adaptive immunity has the ability of assembling antigen-binding molecules 
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with specificity for individual microbial and environmental structures. It also includes immune 
memory. It produces long lived cells that can persist in an inactive state. Effector functions can 
be re-expressed rapidly when these cells encounter their antigens for a second time.43, 44 The 
cells of the adaptive immune system are T and B lymphocytes. B-cells produce antibodies and 
can form memory cells with the ability of rapid antibody production in future encounters with 
the same pathogen. T-lymphocytes can be divided into subtypes according to their functions 
and lineage markers, such as CD4 and CD8. CD4+ cells recognize antigens through 
presentation of major histocompatibility complex (MHC) class II molecules and produce 
cytokines as helper-T-cells. CD8+ cells are activated by antigens presented by MHC class I 
molecules and form cytotoxic T-cells to destroy virally infected cells and tumor cells. Memory 
T-cells are a subset of T-cells that persist after an infection is gone, and may be either CD4+ or 
CD8+. Regulatory T-cells or Tregs are CD4+ cells that inhibit immune responses and prevent 
autoimmunity.45 
1.6 INFLAMMATION AND CELL INJURY IN NASH 
As stated above NAFLD is a clinicopathologic diagnosis, and liver biopsy is mandatory for the 
diagnosis of NASH. Hepatocytes are organized into plates, separated by sinusoids within the 
lobule. In the middle of each lobule is a central vein. Portal tracts are situated in the corners of 
the roughly hexagonal lobule. The inflammation in steatohepatitis is predominantly lobular, but 
portal inflammation may also occur. In lobular infiltrates a mix of polymorphonuclear cells and 
chronic inflammatory cells (including lymphocytes, monocytes, plasma cells and eosinophils) 
are seen. The portal infiltrates, which are not always present in adults, are composed of 
mononuclear cells. The inflammation in NASH may also include lipogranulomas. 
Hepatocellular injury may result in ballooning or acidophilic degeneration.46   
The mechanisms of NAFLD development are not fully understood. An early model is the two-
hit hypothesis presented by Day and colleagues. Accumulation of fat renders the liver 
susceptible to a second hit. There have been various candidates for the second hit. Since 
NAFLD often is described as the liver manifestation of the metabolic syndrome, insulin 
resistance might be the cause of both hits,28 but as stated above, current opinion stress the 
probable interactions of various underlying mechanisms. There have been proposals that 
increased endotoxin levels could be a second hit. Obesity has been associated to gut 
permeability leading to increased levels of bacteria and endotoxins in portal circulation. Toll-
like receptors (TLR), as part of the innate immune response, can recognize microbes as well as 
respond to free fatty acids and might be of importance in the pathogenesis of obesity related 
inflammation and insulin resistance. It has been shown that activation of TLR-4 can induce the 
production of pro inflammatory cytokines in macrophages and epithelial cells.47 Much evidence 
supports a key role for interleukin-6 (IL-6) and tumor necrosis factor α (TNF-α) in NASH.  
These pro inflammatory cytokines has been found to be increased in human fat cells from 
patients with obesity and insulin resistance.48, 49 Regulatory T-cells (Tregs) seem to be of 
importance in hepatic immune regulation. Tregs have been identified as CD4 (+), CD25 (+), 
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and forkhead box protein 3 positive (Foxp3 (+)). Tregs are thought to have a positive effect on 
tumor growth by suppressing antitumor immune cells.50 Inadequate Treg regulation contributes 
to chronic hepatitis B/C virus infection and autoimmune liver disease.51-53 Whether or not Tregs 
play a role in the pathogenesis of NASH had not yet been investigated at the time of our study. 
Tregs as well as other T-lymphocytes express lymphocyte function associated antigen-1 (LFA-
1) to adhere to endothelial cells expressing inter cellular adhesion molecule-1 (ICAM-1). 
ICAM-1 is important for leukocyte endothelial transmigration. A positive correlation between 
inflammation and the levels of ICAM-1 has been shown in NAFLD.54 
1.7 DYSMETABOLIC IRON OVERLOAD 
Iron accumulation in the liver is considered to be a co-factor for progression of liver disease. 
Hyperferritinemia and positive liver iron stains occur frequently among patients with NAFLD. 
This condition was originally named “Insulin-resistance associated iron overload”. Today the 
term dysmetabolic iron overload (DIO) is commonly used. Since oxidative stress seem to 
explain liver injury in relation to iron overload as well as in NASH there has been proposals 
stating that iron might be an important pathogenetic factor in NASH.55 The role of the 
hemochromatosis mutation C282Y in relation to NASH has been investigated. George et al. 
found that this mutation was responsible for most of the mild iron overload found in NASH.56 
In a study by Bonkovsky et al. the prevalence of HFE-mutations (C282Y and H63D) was 
significantly higher in patients with NASH compared to controls. They also found that patients 
with C282Y mutations had more hepatic fibrosis than those without.57 There are also 
contradicting studies that have failed to prove the association of HFE-mutations and NASH,58, 59 
indicating that the high prevalence of these mutations among NASH patients might be due to 
selection bias. Bugianesi at al. found that increased ferritin levels were a marker of severe 
histologic damage in NAFLD, but not of iron overload. Iron overload and HFE-mutations did 
not significantly contribute to hepatic fibrosis in the majority of patients with NAFLD.60 Thus, 
even though the importance of HFE-mutations in the development of DIO is debated, 
hyperferritinemia with or without mild to moderate iron overload is still a common finding in 
NAFLD.61, 62  Although it is still not known if iron reduction therapy in NAFLD-patients with 
iron overload can improve clinical endpoints such as fibrosis or complications of type 2 
diabetes, there are studies that are supportive of such treatment due to its beneficial effects on 
insulin sensitivity, and observations of a tendency towards histological improvement.63-65 
Treatment in NAFLD and NASH is aimed at improvement of metabolic control and thus the 
cornerstone ought to be life-style interventions (which sometimes are difficult to implement). 
Pharmacotherapy has not yet provided the clinician with so many options.66 In clinical practice 
iron reduction therapy is often employed in patients with NAFLD and concurrent DIO. 
Elevated serum ferritin seems to be a marker of histologic severity in NAFLD,60, 67  but cannot 
be used for detection of patients with iron overload. Magnetic resonance imaging is a non-
invasive alternative to liver biopsy in diagnosing hepatic iron overload that has proven useful,68 
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but still, the search for new markers of iron overload is important, since they would be of great 
use in a clinical setting.  
The possible contribution of iron in disease progression in NAFLD has focused attention on the 
iron regulatory hormone hepcidin. Depressed hepcidin synthesis has been described in other 
chronic liver diseases. Alcohol may induce down-regulation of hepcidin, causing iron overload 
in alcoholic liver disease (ALD). Hepatitis C virus infection seems to suppress hepcidin, also 
causing iron retention.69, 70 There are several studies on hepcidin in NAFLD but the results are 
not conclusive. Aigner et al. found increased hepatic expression of hepcidin as well as a down 
regulation of the iron export protein ferroportin-1 and the iron sensing molecule hemojuvelin in 
iron overloaded NAFLD patients.71  Nelson et al. investigated the relationship between serum 
hepcidin levels, histology, including iron deposition, and HFE genotype in patients with 
NAFLD. They found an association between lower hepcidin levels and increased hepatocellular 
iron overload in patients carrying the C282Y mutation. However they also found that the HFE-
genotype did not affect the physiologic up regulation of hepcidin in accordance to hepatic iron 
overload, thus concluding that body iron stores are the determining factor of hepcidin regulation 
in NAFLD.72 There are studies, however, that come to different conclusions. Zimmermann et al. 
studied patients with the metabolic syndrome, with or without NASH, but no iron overload. 
They found higher hepcidin levels in patients compared to healthy controls. Hepcidin correlated 
with ferritin and lobular inflammation in all patients, and with small dense low density 
lipoproteins and insulin resistance index in NASH. They suggest hepcidin as a potential marker 
for hepatic inflammation with possible linkage to lipid and carbohydrate metabolism in 
NASH.73 Barisani et al. studied iron related gene expression in DIO patients. No alternations 
were found as hepcidin mRNA correlated with the expression of its regulators. A significant 
correlation between hepcidin and indices of lipid metabolism was observed leading to 
speculations on interactions between hepcidin and dyslipidemia.74 This is in line with the work 
by Senates et al. who studies hepcidin levels in NAFLD patients. They found hepcidin levels to 
be higher in patients compared to age and sex matched healthy controls. There was a significant 
correlation between hepcidin and total cholesterol and triglycerides, but no association to iron 
parameters or histology.75 Hepcidin levels have also been studied in the case of morbidly obese 
patients undergoing bariatric surgery. In a study by Vuppalanchi et al. obesity was associated to 
hepcidin levels, but there was no correlation to NAFLD including liver histology, (However this 
study did not include assesement of iron stains).76 Bekri et al found an increased expression of 
hepcidin mRNA in adipose tissue of obese patients. In this group the presence of diabetes or 
NASH did not affect hepcidin expression levels either in adipose tissue, or in the liver.77 In 
summary there are different explanatory models of hepcidin regulation in DIO. Some stress the 
putative links to lipid metabolism and obesity which is in line with the possible involvement of 
pro-inflammatory cytokines in the pathogenesis in NASH, while others have found that 
hepcidin levels primarily reflect iron stores.  
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1.8 CRYPTOGENIC CIRRHOSIS 
As mentioned above patients with NASH are at risk of developing progressive liver disease, 
cirrhosis and hepatocellular carcinoma. The term cryptogenic cirrhosis (CC) is used when no 
underlying etiology of the liver disease can be found, and thus is a diagnosis of exclusion. The 
proportion of CC, as compared to all cirrhotic patients, varies and has been estimated to 
between 5-30%.78 The focus on NAFLD and NASH in recent years has evoked the question 
whether or not many cases of CC in fact could be “burned out NASH”.79 A more definite 
diagnosis can be obtained in the case of CC if a more detailed clinical evaluation is carried out 
prior to, or after, orthotopic liver transplantation (OLT), as has been shown in several studies.30, 
80-83  Studies have shown higher frequencies of diabetes and obesity in patients with CC 
compared to those with cirrhosis of known etiologies, leading to the assumption that the 
underlying cause is NAFLD in up to 50% in cases of CC30, 31, 84. However, other studies have 
concluded that a smaller proportion (10-20%) of CC patients have possible NAFLD as the 
underlying diagnosis. Instead there was a higher frequency of patients with burned out 
autoimmune hepatitis.81, 83, 85 Other proposed underlying causes include unknown viral (non-A, 
non-B, non-C) infections, heterozygous alpha-1-antitrypsin deficiency, and alcohol abuse 
unapparent at the time of diagnosis. One would think that the latter could be a fairly common 
explanation, but studies have failed to prove alcohol abuse as a major cause in this setting.86 
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2 AIMS 
The overall aims of this study were to explore the pathogenesis, histological and clinical 
features in patients with chronic liver disease due to steatosis and/or iron overload, with 
special emphasis on HFE mutations, inflammatory regulation, iron homeostasis and end-
stage liver disease in the context of liver transplantation. 
The specific aims of this study were 
 to determine the HFE S65C frequency in a Northern European population, and to 
evaluate whether the S65C mutation would result in a significant hepatic iron 
overload or not. (Study I) 
 to evaluate the presence of NAFLD in patients with cryptogenic cirrhosis evaluated 
for OLT, and to compare survival in OLT candidates with cryptogenic cirrhosis and 
those with cirrhosis of another known origin. (Study II) 
 to correlate amount and type of hepatic fat to inflammation in NAFLD, and 
investigate if not only innate, but also adaptive immunity is involved in NASH. 
(Study III) 
 to investigate if hepcidin levels are altered in patients with NAFLD with or without 
DIO compared to other patients with chronic liver disease with or without hepatic 
iron overload, and to see if these levels correlate to markers of inflammation, 
dyslipidemia and/or altered iron metabolism. (Study IV) 
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3 MATERIALS AND METHODS 
 
3.1 SUBJECTS AND DATA COLLECTION 
3.1.1 Study I 
Patients 
Patients with clinical indications of iron overload were selected from those genotyped for 
HFE mutations at the Division of Clinical Chemistry, Huddinge University Hospital from 
October 1st 1997 to September 19th 2000. All patients having: (1) serum ferritin >300 μg/l 
(males) or >200 μg/l (females); or (2) Tf-saturation >50% (males) or >45% (females) were 
included, except for those patients found by family screening or those related to another 
subject in the study, who were excluded. Another 17 patients were excluded who had 
hyperferritinemia due to acute hepatitis, acute liver failure, hepatocellular carcinoma, 
thyreotoxicosis, acute leukaemia, or myelodysplastic syndrome. In total, 296 patients were 
included in the study. Apart from HFE mutation analysis, values for serum ferritin and/or Tf-
saturation, and hemoglobin count were collected retrospectively from patient files from the 
time of diagnosis (before any phlebotomy treatment had been initiated). In 78 cases, the exact 
serum ferritin value at the time of diagnosis could not be found, and in 90 patients, data on 
Tf-saturation were missing. Clinical data concerning iron staining of liver biopsies (if 
performed), and whether or not patients had undergone phlebotomy were extracted from 
patient files for 231 of 296 patients. Patients with hepatic iron staining of grade 1 or more or 
who had been treated with phlebotomies were classified as having iron overload. 
In patients carrying the HFE S65C mutation, clinical data were collected from patient files. 
Alcohol consumption, hepatitis B and C serology, and activity levels of serum alanine 
aminotransferases were evaluated. In patients diagnosed as having iron overload and 
undergoing phlebotomies, redrawn quantities of blood were noted. 
Controls  
A total of 250 healthy control subjects participated in the study. None had a history of liver 
disease or had received multiple blood transfusions. They were recruited from hospital staff, 
students, and their relatives. Blood samples were collected from each subject for analysis of 
serum ferritin, Tf-saturation, and hemoglobin count. HFE mutation analysis was performed 
on all subjects. 
3.1.2 Study II 
A search in the computerized OLT evaluation register at the Karolinska University Hospital 
in Huddinge was performed in order to find adult patients evaluated for OLT between 1990 
and 2004. Of the 924 evaluations found, 350 were excluded for the following reasons: (a) 
evaluations for re-transplantation (n = 63); (b) evaluations on non-cirrhotic patients such as 
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those with familial amyloidosis with polyneuropathy or acute liver failure (n= 92); (c) 
patients with malignant liver disease (n = 180); and (d) patients with polycystic liver disease, 
Caroli’s syndrome or Budd–Chiari syndrome (n = 15). In patients evaluated twice or more 
only the initial evaluation was included. Of the remaining 574 cases, clinical data could be 
retrieved in 470 consecutive patients, all of whom were included in the study. Of these, 39 
(8.3%) had been diagnosed as having cryptogenic cirrhosis. No patient transplanted later than 
December 31st 2004 was included.  
In the 39 patients diagnosed with cryptogenic cirrhosis, more detailed information was 
obtained regarding alcohol consumption, concurrent autoimmune disease and previous 
response to treatment for presumed autoimmune liver disease by re-evaluation of patient files 
pre- and post-OLT. None of these patients reported a previous or current alcohol 
consumption exceeding 20 g/day in the interview protocol. Signs of autoimmunity were 
defined as either concurrent autoimmune disease (thyroid disease, rheumatoid arthritis, 
inflammatory bowel disease and vitiligo) or elevated autoantibodies and immunoglobulins. 
The written results from previous liver biopsies were accessible in 24 of 39 patients with 
cryptogenic cirrhosis.  
The OLT evaluation register at the Karolinska University Hospital in Huddinge comprises 
prospectively registered data on all adult patients evaluated for OLT since 1989. Data has 
been collected from patient interviews and results of investigations performed at the time of 
evaluation for OLT. Data on diabetes mellitus, history of hypertension, esophageal and 
gastric varices, variceal bleeding episodes and hepatic encephalopathy were recorded. Child–
Pugh and Model for End-Stage Liver Disease (MELD) scores had been calculated for all 
patients. Data also include blood and serum biochemistry (including liver tests), lipid status 
and viral plus immunological markers. Body mass index (BMI) at the time of OLT evaluation 
was corrected by a weight reduction of 5 kg if significant ascites was present. A current 
alcohol consumption > 20 g of ethanol per day had been recorded, and previous alcohol over-
consumption (> 60 g per day) or previous healthcare for alcohol dependency had been noted. 
All patients had been interviewed by an experienced anesthesiologist regarding estimated 
weight loss in the last 12 months prior to the evaluation for OLT, and this had been 
documented in the protocol.  
Patient survival 
Survival dates were recorded until 1 January 2008. Patients not accepted for OLT were 
classified either as being too healthy for OLT or as having bad health and/or other diseases 
precluding OLT. Patients who died during the time of evaluation for OLT were recorded. For 
those patients who were accepted for OLT, patient survival after acceptance on the waiting 
list (intention-to-treat), as well as after OLT (post-transplant), was recorded. 
3.1.3 Study III 
A computer search for in-house liver biopsies at the Department of Gastroenterology at 
Karolinska University Hospital in Huddinge between April 1994 and October 2004 was 
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performed in order to identify patients with persistent abnormal liver biochemistries for more 
than 6 months, and/ or clinical signs of cirrhosis of unknown cause at the time of biopsy. Four 
hundred and five biopsies were found and for these cases clinical data was reviewed. 
Exclusions were made for patients with known alcohol use in excess of 20 g/ day. Biopsies 
from patients with other known liver disease such as viral hepatitis, autoimmune hepatitis, 
drug-induced liver disease, primary biliary cirrhosis, biliary obstruction, hemochromatosis, 
Wilson´s disease, and α-1-antitrypsin deficiency associated liver disease, were excluded. The 
remaining biopsies corresponded to 110 patients who were classified as subjects with high 
suspicion of NAFLD based on clinical data including ultrasound and/or the presence of 
hepatic fat as described in the original liver biopsy protocols. For these patients laboratory 
data were obtained from medical and laboratory records closest to the dates of liver biopsy, 
such as serum alanine aminotransfrease (ALT), aspartate aminotransfrease (AST), alkaline 
phosphatase, gamma-glutamyl transpeptidase (GGT), ferritin, transferrin saturation, total 
cholesterol, total triglyceride and glucose levels. BMI was recorded for all patients. No 
patient had a history of ingestion of drugs known to cause hepatic steatosis, including 
corticosteroids, high-dose estrogens, methotrexate, calcium channel blockers or amidorone in 
the previous 6 months. All biopsies were re-evaluated by a pathologist blinded to patient data, 
and scored according to the NAFLD Activity Score (NAS) as described by Kleiner et al.35 
(See below.) From this cohort we randomly selected 31 patients with the diagnosis of NASH. 
In addition, we selected 18 non-NASH patients having steatosis without inflammation (n=8), 
inflammation and less than 5 % steatosis (n=8), and no inflammation and less than 5% 
steatosis (n=2), respectively.  
3.1.4 Study IV 
Patients with chronic liver diseases and/or hereditary hemochromatosis with or without 
hyperferritinemia were prospectively enrolled in this study at the outpatient clinics at the 
Karolinska University Hospital between January 2008 and April 2013. A total of 85 patients 
were included, 38 of which had NAFLD, 18 hereditary hemochromatosis (HH), ten non-
hereditary hemochromatosis (NHH), and 19 patients with various other causes of chronic 
liver disease (CLD). Among the 18 patients with HH, 12 were HFE C282Y homozygotes and 
six were C282Y/H63D compound heterozygotes. NHH was defined as the clinical phenotype 
of hemochromatosis (elevated serum ferritin and transferrin saturation, and hepatic iron 
overload) but without homozygocity for the HFE C282Y mutation or compound 
heterozygocity for the C282Y and H63D mutations. One patient with NHH had received oral 
iron substitution for several years; however, none had been treated with parenteral iron 
substitution or blood transfusions. In the group of 19 patients with chronic liver disease, nine 
had alcohol overconsumption (>30 g/day), and ten patients had other causes of liver disease 
(primary biliary cirrhosis, hepatitis C, cryptogenic cirrhosis, methotrexate-treated psoriasis) 
with alcohol consumption <30 g/d. None of the patients with NAFLD, HH or NHH had 
reported a previous or current alcohol consumption exceeding 20 g/day.  
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Hyperferritinemia was defined as a serum ferritin >350 µg/L, according to the reference value 
of the Karolinska University Laboratory. All patients were over 18 years of age. One patient 
with iron deficiency (serum ferritin <30µg/L) was excluded. No patients included had been 
subject to treatment with iron reduction therapy before entering the study. Liver biopsy was 
performed in 67 out of 85 patients. MRI was used for iron assessment in 16 cases in which 
histology was lacking. In 21 cases there was both histology and MRI. In two cases (one HH 
compound heterozygote and one with CLD) both liver histology and MRI was lacking. 
The NAFLD-patients were divided into three groups: (1) those with normal ferritin and 
without any signs of iron overload in liver biopsy or on MRI (NAFLD-N; n=15); (2) those 
having elevated ferritin, but no signs of iron overload in liver biopsy or on MRI (NAFLD-
FERR; n=7); and (3) those with elevated ferritin and iron overload (NAFLD-DIO; n=16). 
The chronic liver disease patient group (CLD) was divided into: (1) those with normal iron 
parameters and no signs of iron overload (CLD-N; n=8); and (2), those with signs of hepatic 
iron overload (CLD-IO; n=11). 
Controls 
A total of 40 controls, recruited from hospital staff, with normal or low (<30 µg/l) ferritin 
levels participated in the study. None had a history of liver disease. Of these, two were 
excluded (elevated transaminases in one case, and compound heterozygocity and elevated 
ferritin in the other). A third subject had slightly elevated ferritin (413 µg/l), but was not 
excluded. The remaining 38 controls were divided into two groups: (1) those with normal 
serum ferritin (>30 µg/L; n=25) (denoted normal iron status controls) and (2) those who were 
iron deficient (serum ferritin <30 µg/L; n=13) (denoted iron deficiency controls).   
Biochemical data was collected at the time of enrollment in the study for patients and 
controls. Blood samples were collected before 10 A.M. in the morning. Subjects were not 
fasting but had had a light breakfast. Routine blood chemistry analyses at the Karolinska 
University Hospital were used. 
Body mass index was calculated and HFE-mutation analysis was performed on all subjects. 
3.2 ASSESSEMENT OF LIVER BIOPSIES 
3.2.1 Assessment of liver biopsies in study I 
Liver biopsy had been performed in seven of the 14 patients carrying the HFE S65C 
mutation. These biopsies were re-evaluated in order to refine the data from the written 
protocols in those cases where precise indications concerning iron score and fibrosis stage 
were lacking. Iron deposition in hepatocytes was described using the “hepatocyte iron score” 
(HIS) as described by Deugnier et al.13, with the following modifications: grade 0= no 
stainable iron, grade 1= faint bluish color with small non-coalescent iron granules in zone 1 
hepatocytes, grade 2= iron granules in the majority of zone1 hepatocytes, occasionally 
coalescent, grade 3= marked iron deposition with coalescent granules, and grade 4= massive 
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iron deposition in hepatocytes of the entire lobule. Sinusoidal cell iron deposits were 
described by the “sinusoidal iron score” (SIS) and scored as present =1 or absent =0. Fibrosis 
was staged as follows: stage 0= absent, stage 1= non-extensive portal fibrosis, stage 2= 
extensive portal fibrosis, stage 3= bridging fibrosis, and stage 4= cirrhosis. 
3.2.2 Assessment of liver biopsies in study II 
The written results from previous liver biopsies were accessible in 24 of 39 patients with 
cryptogenic cirrhosis. Biopsies displaying steatosis or steatohepatitis in the written protocol 
were re-evaluated and classified by an experienced pathologist according to Brunt et al.87 
3.2.3 Grading of liver biopsies for NAFLD and NASH (study III and IV) 
All liver biopsies were re-evaluated by an experienced pathologist blinded to clinical data. 
Liver histology was scored in accordance with the system developed by Kleiner and Brunt et 
al.35, 88  Thus the classification was based on the basis of macro- and microvesicular steatosis, 
lobular inflammation, and ballooning degeneration. The stage of fibrosis was also recorded.  
Degree of steatosis was graded 0-3 based on the area of the biopsy occupied by fat: (grade 0: 
< 5%, grade 1: 5-33%, grade 2: 34-66%, and grade 3: >67% of the area occupied by fat). 
Lobular inflammation was graded 0-3 based on the number foci/ 200 magnification (grade 0: 
none, grade 1: <2 foci, grade 2: 2-4 foci, and grade 3: >4 foci). Ballooning was graded 0-2.  
(0:  where no ballooned cells were seen, 1: ballooned cells few or inapparent, and 2: many 
ballooned cells or easily noted.) 
NAS was calculated as the unweighted sum of steatosis (0-3), lobular inflammation (0-3), 
and hepatocellular ballooning (0-2). 
Patients diagnosed with NASH had a NAS-score of ≥5. In study III the term borderline 
NASH was used to define (eight) patients with the score of 4. 
3.2.4 Determination of siderosis in study IV 
Siderosis was determined for all patients semi-quantitatively on histopathologic examination 
of Perls’ stained liver biopsy samples adapted from Deugnier et al. 89 to match available 
levels of magnification: 
A score from 0 to 4 for iron in hepatocytes was determined: (0) granules absent or barely 
discernible at a magnification of 400X; (1) barely discernible granules at a magnification of 
200X but easily confirmed at a magnification of 400X; (2) discrete granules at 100X 
magnification; (3) discrete granules easily confirmed at magnification of 40X, but barely 
discernible at a magnification of 20X; (4) granules obvious at a magnification of 20X, and 
barely visible for the naked eye. RES-iron was also determined and scored as (0) none, (1) 
mild, (2) or more than mild, as described by Nelson et al. 90. In this study, these two scores 
were transformed into a histologic iron score (HIS) ranging from 0 to 5, comprising the score 
for iron in hepatocytes (0-4), plus one point for RES iron in those cases where it had been 
 18 
 
determined as more than mild, or a half point where it has been determined as mild. Iron 
overload was defined as a histologic iron score of ≥1.  
3.3 BIOCHEMICAL ANALYSES, MORPHOMETRY AND MAGNETIC 
RESONANCE IMAGING 
3.3.1 Biochemical data 
Unless otherwise indicated, standard laboratory routine methods at the Karolinska University 
Hospital, have been used. 
3.3.2 Mutation analysis in study I 
Human genomic DNA was extracted from peripheral blood leucocytes using Qiagen Blood  
and Cell Culture DNA Midi Kit (Qiagen GmbH, Hilden, Germany). In the control material, 
identification of mutations in the HFE gene causing the amino acid exchanges C282Y, H63D, 
and S65C was carried out by restriction fragment length polymorphism (RFLP), essentially 
as described previously.22, 91, 92 Electrophoresis was performed on precast polyacrylamide 
gels (GeneGel Excel 12.5/24 Kit) using the GenePhor DNA Separation System (Pharmacia 
Biotech AB,Uppsala,Sweden). Bands were visualized by silver staining (PlusOne DNA 
Silver Staining Kit; Pharmacia Biotech AB, Uppsala, Sweden). All substitutions detected by 
RFLP were confirmed, either by repeating RFLP testing (C282Y) or by automatic sequence 
analysis (H63D, S65C). In the patient material automatic DNA sequence determination was 
used, corresponding to the first half of exon 2 and the whole of exon 4, using the ABI Prism 
Big Dye Primer Cycle Sequencing Kit on an ABI Prism 377 DNA Sequencer (PE Applied 
Biosystems, Norwalk, Connecticut, USA). Screening for the Y250X mutation in the TfR2 
gene was performed in 44 patients by restriction enzyme digestion, according to Camaschella 
and colleagues.93 
3.3.3 Serum levels of ICAM-1 in study III  
Serum levels of ICAM-1 were measured with ELISA (Human sICAM-1 ⁄CD54 
Immunoassay; RnD Systems, MN, USA). 
3.3.4 Morphometric study of fat content in study III 
Fat volume density was determined using a point counting method with a 11 x 11 grid in x 
200 magnification in Nikon Eclips E800 (Nikon, Solna, Sweden) according to Weibel et al.94 
The area of fibrosis was determined with a computer software program, Image J (public 
domain, NIH, MD, USA). The size of the hepatocytes depends on how much fat they contain, 
which thereby influences the number of cells per defined area. In order to compare the 
number of inflammatory cells between patients with different degree of steatosis, a method 
was developed to correct the number of cells positive for inflammatory markers to the whole 
amount of cells by using the known area of fat. That is, if a biopsy contained 0% fat this 
would be the ”true value” since no area was occupied by fat, but if a biopsy contains 50% fat 
the number of positive cells seen are in fact half of what we should see because of the fat 
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occupying 50% of the area. The formula: estimated true number of positive cells = number of 
positive cells counted/ (1-percentage of fat) was used in an attempt to approximate the 
number of cells. 
3.3.5 Immunohistochemistry in study III 
Paraffin-embedded liver sections from the 49 patients were stained with specific antibodies.  
Sections were deparaffinized with xylene and then ethanol. After rehydration, sections were 
blocked in 0.3–3% H2O2, put in unmasking solution Vector, H-3300 (Vector laboratories, 
Buringame, CA, USA), pH 6 and heat activated by press cooker for 10–30 min, treated with 
IMPRESS serum block and incubated with primary antibody overnight at 4°C. For secondary 
antibody IMPRESS was used. The bound antibody was revealed by addition of DAB and 
then counterstained with haematoxylin.  
For immunostaining the following was used: IMPRESS (Vector Laboratories, Buringame, 
CA, USA) system, for Cleaved Caspase-3 (Asp175, rabbit a-human 1:200; Cell Signalling, 
Danvers, MA, USA), CD3 (DAKO, 0452, rabbit a-human, 1:1000; DAKO, Stockholm, 
Sweden), ICAM1 (CD54, Cell signaling 4915, rabbit a-human, 1:30), CD68 (DAKO M0814, 
mouse a-human, 1:1000; DAKO), and TLR4 (eBioscience 14-9917-82, mouse a-human, 
1:20; eBioscience, San Diego, CA, USA).  
The ICAM1-stainings were considered positive for hepatocytes when the staining covered the 
entire outer cell membrane of hepatocytes. The Foxp3: Standard IHC-protocol for paraffin- 
embedded tissue with 3%  H2O2-blocking in methanol, unmasking solution Vector, H-3300, 
pH 6, heat activated by press cooker, blocking with serum, avidin and biotin, primary 
antibody (Foxp3 mouse a-human, Abcam ab 20034; Abcam, Cambridge, UK), concentration 
10 µg ⁄mL and incubated overnight in 4°C. For secondary antibody biotinylated horse a-
mouse (BA-2001, 1:200; Vector) was used. Apoptosis was evaluated immunohistochemically 
using ApopTag (ApopTag Peroxidase In Situ Apoptosis Detection Kit, S7100; Chemicon 
International, Billerica, MA, USA). ApopTag was performed according to the manufacturer’s 
instructions and stained with DAB, then counterstained with Hx and was calculated in three 
different areas; fat area ⁄tissue (defined as none of the other), inflammatory lobular area and 
portal zones (PZ) (hepatocytes one or two cell rows form portal inflammation tracts).The 
results of immunohistochemical staining with specific antibodies were calculated in the entire 
section and then divided with the number of fields viewed in the microscope at magnification 
40 x (1.0 mm2). 
3.3.6 Quantitative assay of hepcidin in serum samples in study IV 
Freshly drawn serum samples from the 85 patients and 38 healthy controls were stored at -
70°C until analysis. Samples were analyzed for hepcidin by a competitive ELISA kit 
(Bachem, Peninsula Laboratories, LLC, CA, United States). Reference ranges established in 
83 normal subjects showed hepcidin levels that ranged 8-76 and 2-50 µg/L for men and 
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women, respectively (2,5-97,5 percentiles). The results were significantly different between 
genders.  
3.3.7 Analysis of cytokines in study IV 
IL-6 and TNFα were measured using Bio-plex Pro Human Cytokine Group 1 kit (Bio-rad 
Laboratories, Hercules, CA, USA) according to the manufacturer’s instructions. Briefly, 
plasma/serum was diluted 1:4 using Bio-plex sample diluents. To obtain the nine point 
(including blank) standard curve, the kit standard was reconstituted and diluted fourfold. The 
10x IL-6 and TNFα coupled beads was diluted in kit assay buffer and added to all standard 
and sample wells. The plate was incubated on shaker 30 min. After washing IL-6 and TNFα 
biotinylated detection antibodies were added and the plate was incubated as above. In the 
final step PE-conjugated Streptavidin was added and the plate was run on a Magpix 
instrument (Luminex Corporation, Austin TX, USA) and analyzed with xPonent software 
(Luminex). 
3.3.8 Analysis of hepcidin mRNA in liver biopsies in study IV 
Thirty-nine liver biopsies were collected from selected patients, immediately immersed in 
RNA-later and stored at -70C until processed. Total RNA was retrieved from 36 of the 39 
utilized liver biopsies with a dry weight of 0.3-5.9 mg using the RNAqueous -4PCR kit 
(Ambion PN AM1914). Recovered quantities of RNA ranged from 13-200 ng/µL. The 
quality and quantity of the extracted RNA was verified with the Bio-Rad Experion 700-7000 
electrophoresis system, and only samples with an RQI > 8 were included in the study. cDNA 
synthesis was carried out with the High Capacity Reverse Transcriptase Kit (Applied 
Biosystems), using 65-930 ng of total RNA per sample.  
Quantative analysis of liver mRNA: Determination of specific mRNA levels was performed 
on the 7500 Fast Real Time PCR System (Life Technologies), utilizing three endogenous 
controls (GAPDH, Cyclophilin and HPRT) and a reference sample (liver RNA from a patient 
not eligible for this study).  Two different primer pairs were used for the hepcidin analyses 
(denoted Hepcidin Harvard and Hepcidin Saku). All cDNA samples were diluted 1:5, and 
utilizing a sample volume of 2 µL, each sample was run in triplicates with power SYBR 
Green PCR master mix (Life Technologies PN 4367659) and 0.1 µM of each primer. 
Relative expression levels were calculated by the ΔΔCt method, utilizing the 7500 Software 
v.2.0.6. The threshold was set to 0.2, utilizing a defined baseline between 3 and 13 cycles for 
all PCR primer sets. The efficiency was set to 90 % for Cyclophilin and GAPDH, 110 % for 
HPRT and 100 % for both the hepcidin primer pairs. Replicates with a S.D. >0.5 were 
omitted from the analysis. The efficiency of the PCR reactions were evaluated  by using a 6-
fold dilution series of the reference sample, and was found to vary between  90-110%.  
3.3.9 Magnetic resonance imaging in study IV 
Magnetic resonance (MRI) imaging was used for detection and quantification of liver iron 
overload in 35 patients and correlated to histology in 17 of these. Liver iron was assessed 
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semi-quantitatively as has been described by Gandon et al.95 (Their calculation algorithm is 
available at http://www.radio.univ-rennes1.fr/Sources/EN/HemoCalc15.html).  
In the correlation analyses of serum hepcidin to liver iron content, MRI iron was 
approximated to histologic liver iron (HIS) score as follows: <60 µmol/g iron = HIS 0; 60-
100 µmol/g = HIS 1; 101-150 µmol/g = HIS 2; 151-200 µmol/g = HIS 3; 201-250 µmol/g = 
HIS 4; >250 µmol/g iron = HIS 5. 
3.4 STATISTICAL ANALYSIS 
Student’s t-test for unpaired data was used for comparing two groups assuming a normal 
distribution. The Mann-Whitney test was used when comparing non-parametric data between 
two groups. Numerical values of laboratory parameters were analyzed using one-way 
ANOVA and validated for equal variance and normal distribution. Kruskal-Wallis ANOVA 
was used when the assumptions of normal distribution did not hold.  Results were presented 
as mean ± SEM or mean and range. All p-values were presented as two-tailed.  
The relationship between two categorical variables was examined with Chi2-test or Fisher’s 
exact test (when applicable). Pearson´s correlation or simple linear regression was used for 
correlations. 
In study II, patient and graft survival after acceptance for OLT (intention-to-treat survival) 
and after liver transplantation (post-transplant survival) were assessed by Cox regression 
analysis with a score test to calculate the hazard ratios, and Kaplan–Meier survival plots. 
In study IV, the correlation between two numerical variables was analyzed with simple linear 
regression validated for linearity, variance between observations and for normal distribution. 
In the cases where the assumptions did not hold the Spearman’s rank order correlation was 
used instead. Multiple linear regression was used for variables that were significantly 
correlated in the simple linear regression in study IV.  
A p-value < 0.05 was considered statistically significant. 
3.5 ETHICAL APPROVAL 
Study I was approved by the ethics committee at Huddinge University Hospital. Studies II-
IV, were approved at the ethics committee at Karolinska University Hospital.  
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4 RESULTS 
 
4.1 STUDY I 
The HFE S65C mutation was found in 14 patients and eight controls. In controls, the S65C 
allele frequency was 1.6%. The S65C allele frequency was enriched in non-C282Y non-
H63D chromosomes from patients (4.9%) compared with controls (1.9%) (p<0.05).  
Table 1. Number of patients and controls with the C282Y and H63D mutations, and allele 
frequencies of the S65C mutation in alleles without the amino acid substitution C282Y or 
H63D. 
C282Y H63D No of patients 
(n=296) 
No of controls 
(n=250) 
S65C alleles 
(patients) 
S65C alleles 
(controls) 
+/+ -/- 84 1 - - 
-/- +/+ 7 7 - - 
+/- +/- 21 2 - - 
+/- -/- 30 27 2/30 (0.067) 1/27 (0.037) 
-/- +/- 52 41 3/52 (0.058) 1/41 (0.024) 
-/- -/- 102 172 9/204 (0.044) 6/344 (0.017) 
    14/286 (0.049)** 8/412 (0.019)** 
**p=0.0449 (Fisher´s exact test) 
  
Serum ferritin was significantly increased in controls carrying the S65C mutation compared 
with those without HFE mutations. Fifty per cent of controls and relatives having the S65C 
mutation had elevated serum ferritin levels or transferrin saturation. The number of iron 
overloaded patients was significantly higher among those having HFE S65C compared with 
those without any HFE mutation. Half of patients carrying the S65C mutation (7/14) had 
evidence of mild or moderate hepatic iron overload but no signs of extensive fibrosis in liver 
biopsies. 
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Table 2. Genotype, biochemical iron parameters, and clinical data in unrelated patients 
carrying the S65C variant. 
 
Pat 
No. 
Sex Genotype Age (y) Ferritin 
(µg/l) 
TS 
(%) 
Diagnosis 
1 M C282Y/S65C 24 238 77 Mild iron overload 
2 F C282Y/S65C 60 324 48 Healthy, surveillance 
3 F H63D/S65C 72 265 55 Healthy, surveillance 
4 M H63D/S65C 49 536 31 Mild iron overload, AAT def. 
5 M H63D/S65C 68 1463 53 Moderate iron overload, diabetes 
mellitus 
6 F S65C/N 55 251 41 Mild iron overload 
7 M S65C/N 64 566 44 Mild iron overload 
8 F S65C/N 63 205 26 Mild iron overload 
9 F S65C/N 72 364 41 Steatosis 
10 M S65C/N 58 621 28 NASH, mild iron overload 
11 F S65C/N 71 211 56 Ferritin normalized 
12 M S65C/N 64 537 26 Diabetes, hypertension, angina 
pectoris 
13 M S65C/N 69 690 48 Emphysema. Alcohol consumption 
40-60 g/d 
14 F S65C/N 47 50 50 Healthy 
TS, transferring saturation; NASH, non-alcoholic steatohepatitis 
Screening of relatives revealed one S65C homozygote that had no signs of iron overload. 
Compound heterozygosity with S65C and C282Y or H63D did not significantly increase the 
risk of iron overload compared with S65C heterozygosity alone. 
 
 
4.2 STUDY II 
Seventeen (44%) of the cryptogenic patients had NAFLD in a prior liver biopsy and/or 
clinical features of the metabolic syndrome. Two patients had occult alcohol over 
consumption and one patient had burnt-out AIH.  
Cryptogenic patients had significantly higher frequencies of diabetes, ascites, and 
hyponatremia. There was no difference in BMI, however weight loss the last 12 months was 
significantly higher among patients with cryptogenic cirrhosis. 
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Table 3. Clinical data of patients with cryptogenic cirrhosis and of those having cirrhosis of 
other etiologies evaluated for liver transplantation. (data are expressed as mean ± SD or as 
number of patients with percentages in parentheses) 
 Cryptogenic cirrhosis 
(n=39) 
Cirrhosis of other 
etiologies (n=431) 
p 
Females 21/39 (54) 171/431 (40) NS 
Age at time of evaluation (y) 49 ± 9 49 ± 11 NS 
BMI (kg/m2) 24.5 ± 4.8 24.6 ± 4.1 NS 
Self-reported weight loss in last 
year (kg) 
10.1 ± 13.8 (11.9% of 
BW) 
4.3 ± 6.5 (5.5% of 
BW) 
< 0.01 
Diabetes 10/39 (26) 50/431 (11.6) < 0.05 
Ascites 33/37 (89) 279/411 (68) < 0.01 
Sodium (135-145 µmol/l) 134 ± 6 136 ± 6 < 0.05 
BW, bodyweight; NS, not significant 
. 
Patient survival was similar between cryptogenic patients and cirrhotics with a known 
etiology. 
 
Figure 3. Patient survival 
(A) Kaplan–Meier survival plot 
demonstrating survival after 
acceptance for OLT in patients with 
cryptogenic cirrhosis (n = 21) and 
those with cirrhosis of other 
aetiologies (n = 223) (Cox regression 
analysis). There is no statistically 
significant difference between groups 
(hazard ratio 0.71, p = 0.37).  
 
(B) Survival after OLT in cryptogenic 
cirrhosis (n = 19) versus cirrhosis of 
other aetiologies (n = 202) (hazard 
ratio 0.55, p = 0.18). 
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4.3 STUDY III 
Scoring of the amount of fat both by estimation according to NAS-classification and by using 
a morphometric method showed discrepancies that could be attributed to the presence of 
microvesicular fat. Microvesicular fat was increased in high NAS patients and also correlated 
with the total volume of fat. ICAM-1 positive hepatocytes were seen in NASH and were 
absent in non-NASH patients. In addition, ICAM-1 positive hepatocytes were localized to 
areas with microvesicular fat. The sICAM-1 was significantly higher in NASH-patients than 
in non-NASH patients. 
 
  
Figure 4. Immunohistochemical stainings of ICAM-1 (A and B). Positive staining was found 
around hepatocytes in areas of microvesicular fat in biopsies from NASH-patients. 
 
 
Figure 5.  
Patients with NASH had larger areas of CD68 positive cells when corrected for the amount of 
fat. NASH-patients also displayed a higher amount of Foxp3 positive cells, than non-NASH 
Serum levels of sICAM-1 in 
patients with NASH and 
non-NASH (controls). 
Patients with NASH had 
significantly higher serum 
levels of sICAM-1 than 
non-NASH subjects, p = 
0.0015. 
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patients. The quota of Foxp3/CD3 positive cells differed significantly between NASH/ 
borderline-NASH-patients and non-NASH patients (p=0.0236). 
 
 
Figure 6. 
 
 
Figure 7. 
 
 
 
 
 
 
 
The area of CD68 positive 
cells in biopsies corrected 
for the amount of fat in the 
tissue. Results are grouped 
according to NAS results. 
NASH-patients did have 
significantly larger area of 
CD68 positive cells than 
non-NASH and Borderline 
NASH, p = 0.0011. 
The ratio of Foxp3/CD positive 
cells in the lobule from IHC, 
biopsies grouped according to 
NAS results. There was a 
significant difference in the 
quota between non-NASH and 
borderline/NASH-patients, p = 
0.0236. 
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4.4 STUDY IV 
Serum hepcidin values for the different patient groups and controls are shown in Figure 8.  
 
 
Figure 8. Serum hepcidin levels in the different patient groups. The box plots show the median, the 
interquartile range and the min-max values. Hepcidin levels were significantly increased in non-
hereditary HH (in the graph denoted as HFE-wt HH), and for NAFLD-DIO, compared with iron 
deficiency controls, NAFLD-N, homozygous HH and chronic liver disease with normal iron stores 
(CLD-N) (Kruskal-Wallis ANOVA, p<0.05).  
Simple linear regression showed a good correlation between histologic iron score and hepatic 
iron content determined by MR (r2=0.77, p<0.01). There was also a good correlation between 
serum hepcidin and hepcidin mRNA (r2=0.39, p< 0.01).  
Hepcidin levels were increased in patients with iron overload (except for patients with HH), 
including NAFLD-DIO, and correlated to liver iron stores. Ratios between hepcidin and iron 
score is shown in Figure 9. NAFLD-FERR had significantly higher ratios compared to other 
groups.  
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Figure 9. The ratios between serum hepcidin and hepatic iron contents (“iron score”). The 
calculation of iron scores are described in Methods. Patients with a hepatic iron score of 0 (NAFLD-
N) are excluded from the ratio calculation. Patients with homozygous HH had significantly lower 
ratios, and NAFLD-FERR significantly increased ratios, compared with the other groups.(Kruskal-
Wallis ANOVA, p<0.05). (NHH is denoted as HFE-wt HH in the graph). 
 
 
In NAFLD, hepcidin correlated to serum ferritin (r2=0.20, p< 0.01) and liver iron (r2=0.27, p< 
0.05) but not to BMI, CRP, NAS or steatosis. Patients with NAFLD-DIO had significantly 
higher transferrin saturation (0.40±0.08) than NAFLD-FERR (0.25±0.10), p< 0.05. The 
hepcidin-to-liver iron ratio was highest in NAFLD-FERR, and there was a trend towards 
increased inflammatory markers in NAFLD-FERR. Serum hepcidin correlated inversely with 
serum leptin in NAFLD patients (r2=0.14, p< 0.05).  There was a trend towards increased 
portal inflammation in NAFLD-FERR, but without statistical significance. Steatosis, lobular 
inflammation, ballooning, fibrosis and NAS-score did not differ between groups. Clinical and 
laboratory findings in patients with NAFLD are demonstrated in Table 4. 
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Table 4. Clinical and laboratory findings in patients with NAFLD and dysmetabolic iron 
overload (DIO), elevated serum ferritin but normal iron stores (NAFLD-FERR), and normal 
serum ferritin (NAFLD-N), respectively (mean ± S.D.) 
 NAFLD-DIO (n=16) 
NAFLD-FERR 
(n=7) 
NAFLD-N  
(n=15) 
BMI (kg/m2) 28.1±2.4 29.4±2.7 31.4±5.0 
Serum ferritin (µg/L) 816±285* 621±170 156±78 
Serum hepcidin (µg/L) 53±28* 37±13 24±19 
Ratio hepcidin/ferritin 0.07±0.04* 0.06±0.04* 0.19±0.19 
Transferrin saturation (%) 0.39±0.09*# 0.25±0.10 0.27±0.07 
Liver iron score 2.13±0.92*# 0.14±0.24 0.03±0.13 
 n=13: n=6: n=11: 
Triglycerides (mmol/L) 1.95±0.90 1.83±1.09 2.89±1.09 
Cholesterol (mmol/L) 5.25±0.71 5.25±0.84 5.18±0.96 
 n=13: n=6: n=9: 
Leptin (µg/L) 15.8±8.65 21.2±17.0 16.2±9.09 
*=p<0.05(vs. NAFLD-N) 
#=p<0.05(vs. NAFLD-FERR)  
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5 GENERAL DISCUSSION 
The rapid global increase of obesity and type 2 diabetes mellitus is paralleled by an increase 
in NAFLD, thus representing a challenge to general practitioners as well as hepatologists. 
The state of knowledge has improved substantially over the years, and what was considered a 
completely benign condition a couple of decades ago, is now recognized as a major health 
problem. Why some patients with NAFLD progress to NASH with the risk of developing end 
stage cirrhosis and hepatocellular carcinoma, while others do not is still not fully understood. 
Dysmetabolic iron overload is common in NAFLD, and iron overload as a potential 
pathogenic factor has attracted much interest in this diagnosis as well as in chronic liver 
disease in general.  
The HFE gene was identified in 1996, and homozygocity for the HFE C282Y mutation 
accounts for approximately 90% of hereditary hemochromatosis (HH) in Sweden.96, 97  
Compound heterozygocity for C282Y/H63D is much less common and is also associated to 
less severe iron overload compared to C282Y homozygocity.98, 99 Also, a third mutation in 
the HFE gene, S65C was found a few years later. At the time of our study (Study I), it´s 
clinical importance was still controversial. We found that the S65C allele was enriched in 
non-C282Y and non-H63D chromosomes from patients with clinical signs of iron overload 
compared to healthy controls. These findings were in line with results reported in a French 
study by Mura et al.22 In control subjects we could also confirm the HFE mutation 
frequencies from other studies in subjects of Northern European ancestry.20, 22, 100 When we 
studied patients carrying the S65C mutation in detail we found that half of them had signs of 
mild to moderate hepatic iron overload, but no signs of extensive fibrosis. When investigating 
the relatives of one patient we found a S65C homozygous subject (the patient’s mother) who 
had signs of iron deficiency, probably due to menstrual blood loss. The patient’s brother who 
carried the same genotype: C282Y/S65C, had normal ferritin and only slightly elevated 
transferrin saturation. We concluded that S65C is likely to constitute a negligible risk for iron 
associated liver cirrhosis. And as stated above, there are no studies that have associated the 
S65C mutation to extensive liver fibrosis. In retrospect, 4 out of 14 patients in our study had 
either NAFLD or diabetes. A potential role for the H63D mutation in NAFLD pathogenesis 
has been suggested by Nelson et al.72, if such a link could be attributed to the S65C mutation 
is this far entirely hypothetical. However, the question sheds light on the complexity of 
chronic liver disease where multiple factors probably are likely to interact in the disease 
process. 
The finding of the iron regulatory hormone hepcidin helped clarify the context of iron 
overload in several conditions, for instance, the hepcidin deficiency in hereditary 
hemochromatosis, and the impaired synthesis in chronic liver disease such as alcoholic liver 
disease. The role of hepcidin in the case of NAFLD and DIO seems more complicated. As 
described above, there are studies that conclude that the hepcidin regulation in NAFLD is 
normal, while others stress the putative link to fat and inflammation. This discrepancy is not 
completely surprising when recapitulating the topic of hepcidin regulation. There are four 
 31 
 
pathways controlling the hepcidin production in hepatic cells: First the plasma iron regulation 
pathway involves circulating transferrin-bound iron that will compete with HFE in binding to 
transferrin receptor 1 (TfR 1), which promotes hepcidin production via the formation of the 
TfR 2/HFE complex. Secondly, in the erythropoetic pathway, blood loss, anemia and hypoxia 
will lead to erythropoetic stimuli and a subsequent decrease in hepcidin production, thus 
making more iron available. Thirdly, the inflammatory regulation pathway is mainly induced 
by IL-6 and leads to hepcidin excess, causing anemia. Finally, the control of HJV on the 
BMP/SMAD signaling pathway has been described as mandatory in hepcidin regulation.101, 
102  
In our study (Study IV) we studied hepcidin levels, inflammatory markers and lipid profiles 
in patients with various liver diseases and ferritin levels, focusing on NAFLD. The advantage 
of this approach is that we can compare several carefully defined subgroups. A disadvantage 
is the low number of subjects in some of the groups (i.e. NAFLD-FERR). We investigated 
serum hepcidin levels in 85 patients with NAFLD, hemochromatosis and other chronic liver 
diseases, and in 36 of these we correlated serum hepcidin to mRNA in liver tissues. We found 
a good correlation between hepatic hepcidin mRNA and serum hepcidin measured by 
ELISA. Among the 23 NAFLD patients having elevated ferritin in our study, the majority (16 
patients) had DIO, whereas seven patients were found to have elevated ferritin but normal 
iron stores. In all NAFLD patients, hepcidin levels correlated strongly to iron indices such as 
serum ferritin and transferrin iron saturation, as well as to hepatic iron contents. The 
hepcidin-to-hepatic iron score ratio was significantly increased in patients with elevated 
ferritin and normal iron stores (NAFLD-FERR). One may speculate that the increased 
hepcidin levels in these patients are a result of a low-grade chronic inflammation, 
simultaneously increasing serum ferritin levels, and there was a trend towards increased 
TNFα and IL-6 levels among these patients. Thus, a subgroup of NAFLD patients may have 
a low-grade inflammation contributing to increased serum ferritin and hepcidin levels, which 
would then not lead to hepatic iron accumulation and DIO. This is paralleled by the 
observation of a higher fraction of portal inflammation in biopsies from NAFLD-FERR 
patients. Unfortunately, the number of patients in this “inflammatory-NAFLD” group is too 
small in the present study to draw firm conclusions regarding the contribution of low-grade 
inflammation to hyperferritinemia and elevated hepcidin in NAFLD. Our study was not 
designed to discriminate between NAFLD-DIO and “inflammatory-NAFLD”, but rather to 
study hepcidin levels in NAFLD patients compared with patients having other liver diseases, 
with or without iron overload. Thus, further studies are needed on a larger NAFLD cohort to 
explore the hypothesis of the existence of two NAFLD subgroups: “NAFLD-DIO” and 
“inflammatory NAFLD with hyperferritinemia”. When calculating the hepcidin levels in 
relation to the hepatic iron content, i.e. the ratio between hepcidin and liver iron score, 
patients with DIO had a similar ratio as patients with other chronic liver diseases with iron 
overload, that is patients with other chronic liver disease and iron overload and non-
hereditary hemochromatosis, indicating that hepcidin synthesis in DIO is regulated similarly 
as in other chronic liver diseases.  
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We found that transferrin saturation was significantly higher in NAFLD patients with DIO 
compared to those with increased ferritin and normal iron stores. This result indicates that 
transferrin saturation might be used as a marker to differentiate between these two patient 
groups. Such a readily available marker could be of good use in clinical practice, since 
dysmetabolic iron overload may need treatment with phlebotomies, which is not the case in 
“inflammatory NAFLD with hyperferritinemia”.  
In our study, we found no correlation of serum hepcidin with BMI, serum cholesterol, serum 
triglycerides, hepatic steatosis, or NASH activity score (NAS). As mentioned previously 
there are studies that have reached different results. The studies by Barisani et al, and Senates 
et al. found correlations between hepcidin and cholesterol and triglycerides suggesting 
interactions with lipid metabolism.74, 75 In studies on morbidly obese patients, obesity was 
associated to hepcidin levels, but these studies have not found correlations to NAFLD 
including histology or diabetes.76, 77  The NAFLD patients in our study had only slightly 
increased BMI as compared to patients with other liver diseases, and the situation in morbidly 
obese subjects with markedly increased body fat may prove different. The majority of our 
NAFLD patients had either iron overload or a possible “inflammatory NAFLD with 
hyperferritinemia”, which are conditions that strongly induce hepcidin synthesis, which could 
mask a weaker association between hepcidin and cholesterol or triglycerides. There is a tight 
relationship between iron deficiency and obesity. Proinflammatory cytokines such as IL-6 are 
secreted by the adipose tissue and can induce hepcidin expression. Furthermore there is a 
production of hepcidin in adipose tissue, although it is not clear if this could represent a 
significant proportion.9, 103 Interestingly, we found an inverse correlation between serum 
hepcidin and leptin, which is in conflict to other studies performed on obese subjects. Again, 
the situation in our patient cohort differs from those findings, since our patients have only 
slightly elevated BMI but all had significant hepatic steatosis and the majority elevated serum 
ferritin. Our finding has to be confirmed by others in the same context; i.e. NAFLD with liver 
disease but only moderate overweight. 
HFE mutations have been described as being more common in patients with NASH. In the 
present study, we could not find an increased frequency of C282Y or H63D mutations in 
NAFLD patients with dysmetabolic iron overload as compared to patients with other liver 
diseases, or healthy controls. However, the H63D mutation was enriched in NAFLD patients 
with normal iron stores. This finding indicated that this mutation may play a role in hepatic 
steatosis, as has been mentioned above.  
The “two hit” hypothesis has for long been used as the explanatory model in the pathogenesis 
of NASH. Insulin resistance plays a central role in the “first hit” leading to hepatic steatosis. 
The “second hit” involves oxidative stress, which in turn leads to the development of 
steatohepatitis and fibrosis. The close connection to the metabolic syndrome has led to the 
proposal that insulin resistance could be the cause of both hits. The simplicity of this model 
is obviously appealing, but it has been expanded into the “multiple parallel hits” hypothesis 
in order to take a number of different processes that might contribute to liver inflammation 
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into consideration. Among these are inflammatory mediators derived from adipose tissue 
and the gut, as well as immune system activation. A more detailed model may also 
encompass such observations as inflammation preceding steatosis in certain cases.47, 104  
The NASH activity score (NAS) was introduced in 2005 by Kleiner et al. to be used in 
studies on NAFLD and NASH. The score is based on the unweighted sum of three 
parameters: hepatic fat content, lobular inflammation and ballooning. A score of ≥5 correlates 
with the diagnosis of NASH35. NAS is widely used, but there are those who argue that NAS 
omits crucial information. For example it takes no account of fibrosis, which has been 
addressed in studies of NAS in the context of disease progression and mortality in 
NAFLD.105, 106 In addition, Younossi et al. performed a study in which the original pathologic 
criteria for NAFLD subtypes (as had been described by himself and colleagues in 1998107) 
demonstrated the best predictability for liver related mortality in this patient group.108 
Moreover the term NAFLD covers a broad spectrum of liver disease. The majority are 
patients with simple steatosis. Some will develop steatohepatitis, and these are in turn at risk 
for progression with fibrosis. In this perspective NAS might seem blunt, since a patient with 
pronounced steatosis and very mild inflammation can receive the same score as a patient with 
only mild steatosis and inflammation and/ or signs of necroinflammatory activity i.e. 
ballooning. 
In order to furhter characterize the importance of fat and inflammatory cell distribution in the 
liver parenchyma we performed a study on 49 patients with the clinical diagnosis of NAFLD 
(Study III). Our goal was to investigate if the type and amount of fat is of importance to the 
inflammatory process in NASH, and we also wanted to investigate if both the innate and 
adaptive immunity is involved in NASH. The amount of fat was scored both by estimation 
according to NAS-classification and calculated with a morphometric method as described in 
the methods section. We found that these two values differed in some patients and concluded 
that this discrepancy could be attributed to the presence of microvesicular fat. In NAFLD 
macrovesicular fat is more predominant, but microvesicular fat has been correlated to higher 
NAS as well as more advanced fibrosis.109 This is interesting, since our study showed that 
ICAM-1 positive hepatocytes were located in areas of microvesicular fat deposits. Therefore 
one could speculate that the presence of microvesicular fat may represent a more severe form 
of NASH. Moreover NASH-patients had higher levels of ICAM-1 in serum compared to 
patients with borderline NASH and non-NASH patients. Thus sICAM-1 might be interesting 
in the quest for non-invasive diagnostic tools in the case of NASH. We found an increase in 
the number of Foxp3 positive cells in NASH patients, and higher Foxp3/ CD3 ratio correlated 
to higher NAS. Since Foxp3 is the most specific marker of regulatory T cells (Tregs), this 
finding supports the involvement of adaptive immunity in NASH. Tregs are involved in the 
negative control of various immune responses, such as viral hepatitis and hepatocellular 
carcinoma. The finding of more Tregs and less CD3 cells in NASH-patients could indicate 
that CD3 cells are diminished by Tregs in order to decrease inflammation. (CD3 is used as a 
general T-cell marker). CD68 is a useful marker of cells of the macrophage lineage. When 
the area of CD68 positive cells in biopsies was corrected for the amount of fat we found 
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higher values in NASH-patients in comparison to non-NASH and borderline-NASH patients, 
indicating involvement of innate immunity. However, in our study, we did not find any 
difference in TLR-4 positive cells between groups, which would contradict the idea of gut 
microbiota as an important pathogenic factor in NASH.   
Cleaved Caspase-3 and ApopTag was used for detection of apoptosis, and did not differ 
between groups. Thus, in our study, apoptosis could not be found to be driving inflammation.  
With chronic hepatic inflammation comes the risk of progressive fibrosis and cirrhosis. In 
some cases the cause of the inflammatory process is unclear. Among patients with liver 
cirrhosis, the percentage of those having cryptogenic cirrhosis (CC), i.e., cirrhosis of 
unknown etiology, varies, but has been estimated to be 5-30%. However, CC is diagnosed in 
only 5-7% of patients undergoing orthotopic liver transplantation (OLT) due to cirrhosis.81  
This discrepancy could be explained by a more thorough work-up at the evaluation of 
patients for OLT, or it could indicate that the lack of a more specific diagnosis is a 
disadvantage in end stage liver disease. It is hardly surprising that the focus on NASH over 
the two last decades has prompted the question if this condition could be the underlying cause 
in many cases of CC. Histopathological findings are crucial for the diagnosis of NASH. 
Consequently, there might be an underestimation of cases, since features of NASH may 
disappear during the development of cirrhosis.110 Studies on NAFLD as the likely underlying 
cause in CC have shown varying results, and there is also a difference between American and 
European studies, in which the latter have shown lower frequencies of suspected NAFLD.30, 
31, 81, 83-85   
In our study (Study II) we addressed these questions by comparing 39 CC patients to 431 
patients with cirrhosis of other (known) etiologies who had been evaluated for OLT between 
1990 and 2004. We wanted to estimate the frequency of possible NAFLD in a Swedish 
material, not the least due to the geographical variation in previous studies. We also wanted 
to compare the severity of liver disease and patient survival in OLT candidates in order to 
find out if the diagnosis of CC could be a disadvantage in this setting.  
In our material re-evaluation of clinical data led us to reach an underlying diagnosis in 51% 
of CC patients. Seventeen (44%) of these patients were considered to have possible 
underlying NAFLD. Conditions associated to NAFLD such as type 2 diabetes or a history of 
obesity was encountered in an additional seven patients. Only one patient was found with 
probable autoimmune hepatitis, and two patients with occult alcohol abuse. Consequently, 
our findings are in line with the results from American studies.30, 31, 80, 81, 84-86, 111, 112 The 
reason for the discrepancies between studies are not known, but possible explanations may be 
differences in patient populations, diagnostic work-ups, and whether or not patients were 
investigated in an OLT setting.  
When comparing CC patients to patients with cirrhosis of known etiologies we found 
increased frequencies of ascites, hyponatremia and reported weight loss in the CC group. 
These findings suggest that CC patients have a more advanced liver disease at the time of 
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referral for OLT. However, we lack stronger evidence in this case, since there was no 
difference in Child-Pugh or MELD-scores between the groups.  
Malnutrition is an independent risk factor for poor survival after OLT.113 The patients with 
CC in our study were not malnourished and their BMI was similar to other patients with liver 
cirrhosis of known etiology. However, weight loss during the year before evaluation for OLT 
was significantly higher in the CC group. This is possibly a sign of deterioration of the liver 
disease in these patients and may signal a need for OLT evaluation.  
When comparing the acceptance rate for transplantation there were no differences between 
CC patients and patients with cirrhosis of known etiology. We could observe a tendency 
towards a higher degree of rejections for OLT due to poor health and/ or concurrent disease 
in the CC group, but the difference was not statistically significant. Nor did the comparison of 
survival after being accepted for OLT or after OLT show any difference between the groups. 
When looking on at the subgroup of CC patients with possible NAFLD, the survival results 
were similar. Our results are in line with many other authors that have concluded that CC, as 
well as NASH-cirrhosis are favorable indications for OLT.82, 85, 114, 115 
6 CONCLUSIONS 
In Study I, the frequency of the HFE S65C mutation in a Northern European population was 
1.6%, and it was found to have the potential of causing mild to moderate hepatic iron 
overload, but not extensive liver fibrosis. 
Re-evaluation of data in patients with cryptogenic cirrhosis (CC) from the time of evaluation 
for OLT, in study II, resulted in a probable underlying etiology in more than half of patients, 
NAFLD being the most common diagnosis (44%). In spite of a tendency toward more severe 
liver disease at the time of evaluation for OLT, the survival after OLT for patients with CC 
did not differ from that of patients with liver cirrhosis of known etiology. 
In study III, the amount of microvesicular fat increases with NAS. In liver tissue from 
NASH-patients, hepatocytes with microvesicular steatosis express ICAM-1. The increased 
number of CD68 cells and regulatory T-cells seen in liver tissue from NASH-patient indicate 
that there is an involvement of both innate and adaptive immunity. 
In study IV, hepcidin correlates to iron indices and iron stores, but not to BMI, steatosis, or 
NAS, in NAFLD patients, with or without mild to moderate iron overload. Hepcidin 
regulation in NAFLD did not differ from that seen in other chronic liver diseases apart from 
hereditary hemochromatosis. 
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
I denna doktorsavhandling undersöks olika aspekter av fett- och järnöverskott i levern hos 
patienter med kronisk leversjukdom.  
Det första arbetet handlar om betydelsen av en då relativt nyupptäckt mutation, dvs. 
förändring i ett arvsanlag. I detta fall handlar det om en förändring i den så kallade HFE-
genen. Mutationer i HFE-genen är den vanligaste förklaringen till den ärftliga formen av 
järnupplagringssjukdomen hemokromatos, på våra breddgrader. Sedan tidigare vet vi att de 
flesta fall av ärftlig hemokromatos beror på dubbel uppsättning av C282Y mutationen i HFE-
genen. En variant med C282Y mutationen och H63D mutationen i kombination, kan också 
förekomma. I denna avhandling har vi tittat närmare på en tredje mutation i HFE-genen, 
nämligen S65C. Studien utfördes på patienter med tecken till järnöverskott. Friska kontroller 
fanns med som jämförelsematerial. Vi kom fram till att S65C mutationen var ungefär lika 
vanlig i befolkningen i Stockholmsregionen som i andra jämförbara delar av världen (såsom 
USA och Västeuropa). Vi kunde också se att de patienter som var bärare av S65C-mutationen 
kunde ha ett lätt till måttligt järnöverskott i levern. Däremot fann vi inte någon betydande 
bindvävsomvandling i leverbiopsier (vävnadsprov) från dessa patienter. Studien talar således 
för att bärarskap av S65C mutationen kan vara en förklaring till lätt till måttligt järnöverskott 
i levern, men att risken för mer avancerad leversjukdom pga. sådant bärarskap torde vara 
försumbar.   
Den andra studien fokuserar på patienter med skrumplever av oklar anledning, så kallad 
kryptogen levercirros. Tanken bakom denna studie var bland annat att ta reda på om icke-
alkoholorsakad fettleversjukdom kan vara den bakomliggande orsaken i fall av kryptogen 
levercirros. Studien omfattar noggrann genomgång av de protokoll som används i samband 
med att patienter med skrumplever med olika bakomliggande orsaker utreds för eventuell 
levertransplantation. Upprinnelsen till denna frågeställning kommer av att icke-
alkoholorsakad fettleversjukdom är ett tillstånd som rönt mycket stort intresse på senare år. 
Även i Sverige används vanligen den engelska terminologin i detta fall. Man talar om 
NAFLD (Non Alcoholic Fatty Liver Disease) och NASH (Non Alcoholic SteatoHepatitis). 
NASH är en underdiagnos till NAFLD. Att fettlever är vanligt har man vetat sedan lång tid 
tillbaka, emellertid betraktades icke alkoholorsakad fettleversjukdom som ett i stort sett 
ofarligt tillstånd så sent som på 1980-talet. Senare forskning har visat att patienter med 
NASH löper risk att utveckla levercirros och levercancer. När vi gick igenom journaler och 
protokoll från patienter med kryptogen levercirros kom vi fram till att det fanns en sannolik 
bakomliggande orsak i hälften av fallen. Den orsak, eller diagnos, som var allra vanligast var 
just NAFLD: 17 av totalt 39 patienter. Två andra orsaker var så kallad autoimmun hepatit (1 
patient) och alkoholmissbruk som var okänt vid tiden för levertransplantationsutredningen (2 
patienter). Vidare ville vi ta reda på om det kan vara en nackdel att sakna en specifik diagnos, 
dvs. att läkarna inte vet varför en patient har levercirros. Vi jämförde de 39 patienterna som 
vid levertransplantationsutredningen hade diagnosen kryptogen levercirros med alla andra 
levercirrospatienter med kända diagnoser (exempelvis virala hepatiter, alkoholleversjukdom, 
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autoimmuna leversjukdomar). Vi noterade att patienter med kryptogen leversjukdom var lite 
sämre i sin leversjukdom vid tiden för utredning jämfört med de andra, men trots detta blev 
de inte levertransplanterade i lägre omfattning. Överlevnaden efter levertransplantationen 
visade sig vara lika god för patienter med kryptogen levercirros som för patienter med känd 
orsak till levercirros. När vi tittade närmare på den andel av patienter med kryptogen 
levercirros som sannolikt hade NAFLD som bakomliggande orsak fick vi samma resultat. En 
skillnad mellan patienter med kryptogen levercirros och de andra var hur mycket patienterna 
hade gått ned i vikt under det senaste året. Patienter med kryptogen levercirros hade gått ned 
mer i vikt. Detta skulle kunna vara ett tecken på en försämring i leversjukdomen och kan vara 
en anledning för läkare att överväga en levertransplantationsutredning. 
I den tredje studien tittade vi närmare på mängden och typen av fett i leverbiopsier från 
patienter med NAFLD för att ta reda på om detta har betydelse för inflammation och 
levercellskada hos dessa patienter. Vi ville också ta reda på om den så kallade adaptiva 
immuniteten och inte bara den ospecifika immuniteten är involverad vid NASH.  Med 
adaptiv immunitet avses den del av immunförsvaret som har förmågan att känna igen och 
även minnas det som är främmande på en detaljerad nivå. Vi jämförde patienter med NASH-
diagnos, patienter som låg på gränsen till att ha NASH och andra patienter som hade fett och 
inflammation av olika grad. Vi kunde se att NASH-patienterna hade mer mikrovesikulärt, 
dvs. findroppigt fett jämfört med de andra patienterna. Den inflammatoriska markören 
ICAM-1 var ökad hos NASH-patienterna och lokaliserad till områden med mikrovesikulärt 
fett. Genom att bland annat mäta markörer för så kallade regulatoriska T-celler kom vi fram 
till att både adaptiv och ospecifik immunitet torde vara av betydelse vid NASH.  
Den fjärde studien handlar om det järnreglerande hormonet hepcidin och dess betydelse vid 
NAFLD. Vid så kallad HFE-relaterad hemokromatos, som beskrivits ovan, produceras inte 
tillräckligt med hepcidin. Hepcidin motverkar upptag av järn från tarmen. Således riskerar 
patienter med hemokromatos att med tiden drabbas av ett potentiellt skadligt järnöverskott. 
Vi vet också att hepcidin påverkas av inflammation och att hepcidin inte bara produceras i 
levern, utan även i fettväven. Järnöverskott i levern är vanligt förekommande hos patienter 
med NAFLD. Även om järnöverskottet i detta fall oftast är mildare än hos 
hemokromatospatienter skulle det kunna ha betydelse för sjukdomsutvecklingen hos vissa 
NAFLD-patienter. Vi ville därför undersöka hur hepcidin-nivåer i blod och levervävnad hos 
NAFLD-patienter avspeglar järnöverskott i levern, inflammation, samt blodfetter och 
övervikt. Vi jämförde NAFLD-patienter med och utan järnöverkott i levern med andra 
leversjuka patienter och hemokromatospatienter. Vår studie visade att hepcidinregleringen 
hos NAFLD-patienter inte skilde sig från regleringen hos andra patienter, (förutom de med 
HFE-relaterad hemokromatos, vilket var förväntat). Vi kunde inte se att hepcidinnivåerna hos 
NAFLD patienterna påverkades av övervikt eller blodfetter, vilket vissa andra studier kommit 
fram till.   
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